Delix Logo 1-color

Delix Presents Full Results from Phase 1 Trial of DLX-001 at ACNP Annual Meeting

Must Read
Delix Featured
Delix Logo 1-color

Delix Presents Full Results from Phase 1 Trial of DLX-001 at ACNP Annual Meeting

link
Tessera Logo 1-color

Tessera Therapeutics to Present New Preclinical Data From In Vivo Programs for Sickle Cell Disease and T-Cell Therapies at the 66th American Society of Hematology Annual Meeting

link
Constructive Bio Logo 1-color

Constructive Bio Secures $58 Million in Series A Financing

link
Mythic Therapeutics Logo 1-color

Mythic Therapeutics to Present Data from Phase 1 KisMET-01 Study on MYTX-011 at the American Society of Clinical Oncology (ASCO) Annual Meeting

link
Lightcast Bio Logo 1-color

Lightcast Opens Innovation Center in United States to Support Global Expansion of Luminary Early Access Program

link
Mythic Therapeutics Logo 1-color

Mythic Therapeutics Appoints George Eliades, Ph.D., as President and Chief Executive Officer

link
Freya Logo 1-color

Freya Biosciences Announces $38 Million Funding in One of the Largest Series A Raises to Advance Women’s Reproductive Immunotherapies

link
VedaBio Logo 1-color

VedaBio launches with $40M+ in initial funding for CRISPR-based molecular detection technology

link
Mythic Therapeutics Logo 1-color

MYTX-011 Is Given FDA Fast Track Designation for cMET Overexpressing NSCLC

link
Matterworks Logo 1-color

Matterworks Announces CEO Appointment and Board Updates

link
SyntheX Logo 1-color

SyntheX and Bristol Myers Squibb Enter Into a Research Collaboration to Discover and Develop Targeted Protein Degradation (TPD) Therapeutics

link
Tara Biosystems Logo 1-color

Valo Health Acquires TARA Biosystems Creating First of its Kind Vertically Integrated Cardiovascular Platform

link
# # # #